Figure 2.

Major CrossMab formats: A) 1 + 1 CrossMab:^CH1−CL vanucizumab, faricimab, 10E8.4/iMab 1 + 1; B) 1 + 1 CrossMab^VH-VL±: PD1-TIM3, PD1-LAG3; C) CrossMab^{CH1−CL+/–}based FAP-4-1BBL, CD19-4-1BBL fusion proteins; D) 2 + 1 CrossMab:^CH1−CL cibisatamab; E) 2 + 1 CrossMab^VH-VL±: glofitamab, CC-93269, TYRP1-TCB, WT1-TCB, RG6123; F) 2 + 2 CrossMab^CH1−CL-based FIT-Ig EMB-01, EMB-02, EMB-06; G) 2 + 2 CrossMab:^CH1−CL FAP-DR5; H) 2 + 1 CrossMab ^VH-VL±: BS-GANT, FAP-CD40; I) 1 + 1 CrossMab^CH1−CL-based Nkp46-based NK cell engager (NKCE). Heavy-chain domains are depicted in dark colors and respective light-chain domains are depicted with corresponding bright colors. Fusion protein depicted in purple. Note: Differences in variable regions and/or isotype and Fc engineering are not depicted. Created with BioRender.com